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Objectives. This study sought to determine whether inhibitors
of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reduc-
tase affect CD11b expression and adhesiveness of monocytes in
vitro and after treatment of patients with hypercholesterolemia.
Background. HMG-CoA reductase inhibitors improve survival
of patients with coronary heart disease (CHD) and prevent CHD
in hypercholesterolemic men. Because these drugs have been
shown to modulate monocyte functions, they may act by reducing
monocyte adhesion to endothelium, which is crucial in atherogen-
esis.
Methods. Isolated human blood monocytes were subjected to
flow cytometric detection of CD11b and adhesion assays on fixed
human endothelial cells after treatment with lovastatin in vitro or
ex vivo before and after treatment of hypercholesterolemic pa-
tients with HMG-CoA reductase inhibitors.
Results. The integrin heterodimer CD11b/CD18 expressed on
monocytes interacts with intercellular adhesion molecule-1 on
endothelium and is involved in monocyte adhesion to endothe-
lium. Treatment of monocytes with lovastatin in vitro slightly and
dose dependently reduced surface expression of CD11b on mono-
cytes. Moreover, lovastatin inhibited CD11b-dependent adhesive-
ness to fixed endothelium of unstimulated monocytes or mono-
cytes stimulated with monocyte chemotactic protein 1.
Coincubation with mevalonate, but not with low density lipopro-
tein (LDL), reversed the effects of lovastatin, suggesting that early
cholesterol precursors, but not cholesterol, are crucial for adhe-
siveness of CD11b. In hypercholesterolemic patients, adhesion of
isolated monocytes to endothelium ex vivo was dramatically
increased over values in healthy control subjects. Treatment of
these patients with the HMG-CoA reductase inhibitors lovastatin
or simvastatin (20 to 40 mg/day) for 6 weeks slightly decreased
total and LDL cholesterol plasma levels and monocyte CD11b
surface expression but resulted in a significant reduction of
monocyte adhesion to endothelium (p < 0.01, n 5 7).
Conclusions. The reduction of CD11b expression and inhibition
of CD11b-dependent monocyte adhesion to endothelium may
crucially contribute to the clinical benefit of HMG-CoA reductase
inhibitors in CHD, independent of cholesterol-lowering effects.
(J Am Coll Cardiol 1997;30:1212–7)
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Inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-
CoA) reductase are used in the treatment of hypercholester-
olemia. They improve the survival of patients with coronary
heart disease (CHD) and prevent CHD in hypercholester-
olemic men (1,2). However, the clinical benefits of HMG-CoA
reductase inhibitors such as simvastatin and pravastatin are not
strictly correlated with their lipid-lowering effects (1,3). The
action of HMG-CoA reductase inhibitors on cellular choles-
terol biosynthesis in the liver, blood cells and vasculature may
affect membrane integrity and regulation of membrane-related
processes (4) that are associated with changes in numerous
cellular functions. Cholesterol precursors—i.e., farnesyl or
geranyl pyrophosphates—have been implicated in protein-
protein interactions and protein anchoring to lipid membranes
(5,6), essentially contributing to receptor-stimulated Ca21
increase, superoxide anion formation, low density lipoprotein
(LDL) oxidation, eicosanoid synthesis and differentiation in
monocytic cells (7–10). The functional consequences of these
effects may be relevant for CHD and atherosclerosis, but they
remain to be elucidated in detail.
Monocyte recruitment into the vascular wall is crucial for
the initiation and progression of atherosclerotic lesions (11).
Interaction of the monocytic surface receptor CD11b/CD18, a
beta2 integrin heterodimer, with intercellular adhesion
molecule-1 (ICAM-1) has been involved in the adhesion to and
migration across endothelium of monocytes, particularly when
stimulated (12–14). Hence, we studied the effects of HMG-
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CoA reductase inhibitors on monocyte CD11b surface expres-
sion and adhesion to endothelium in vitro, as well as on
increased adhesiveness of monocytes (15) isolated from hyper-
cholesterolemic patients before and after cholesterol-lowering
treatment. Our study used a recently established ex vivo assay
with fixed human endothelial cells (16).
Methods
Monocyte isolation. Peripheral blood mononuclear cells
(PBMCs) were isolated from 40 ml of anticoagulated blood
collected from healthy donors by using Ficoll density-gradient
separation. To separate monocytes from lymphocytes, PBMCs
were allowed to adhere to plastic for 2 h and subsequently
washed. For treatment with lovastatin, mevalonate (in dimeth-
ylsulfoxide), LDL or 0.1% dimethylsulfoxide (control) at indi-
cated concentrations, monocyte-enriched fractions were cul-
tured in 6-well plates (Corning) in Mono Mac 6 medium (10)
with 10% fetal calf serum or autologous serum in 5% CO2 at
37°C for 24 h. LDL was prepared as described (14). For flow
cytometry and adhesion assays, adherent monocytes were
washed and gently removed with a cell scraper, yielding
purities of ;60%, as judged by CD14 immunofluorescence.
Under all conditions, cell viability was $95%.
In addition, 20 to 40 ml of blood was collected from
consenting patients with isolated hypercholesterolemia before
and 6 weeks after initiation of treatment with lovastatin
(Mevinacor, Merck Sharp & Dohme, 20 to 40 mg/day, n 5 3)
or simvastatin (Zocor, Dieckmann, 20 mg/day, n 5 4) and from
seven age-matched healthy control donors. Treatment with
lovastatin or simvastatin showed similar effectiveness in lower-
ing plasma lipid levels, as well as in reducing monocyte
adhesion. PBMCs were prepared by Ficoll density-gradient
centrifugation, and monocytes were isolated from PBMCs by
magnetic cell separation (Miltenyi) with Fe-dextran conju-
gated CD14 monoclonal antibody (mAb), yielding purities
$85%. The study was approved by the ethical committee of
the University of Munich.
Immunofluorescence. Cells were treated with saturating
amounts of phycoerythrin conjugated monocyte antigen 2
(Mo2) mAb and fluorescein isothiocyanate–conjugated IgM
or phycoerythrin-IgM isotype control and fluorescein
isothiocyanate–monocyte antigen 1 (Mo1) mAb (Coulter) in
phosphate-buffered saline solution with 0.5% bovine serum
albumin for 30 min on ice (17). To avoid binding to Fc
receptors, cells were preincubated with 5% human serum for
15 min on ice. Cells were washed and analyzed with 10,000
cells/sample in a flow cytometer (Becton Dickinson). Mo1
mAb recognizes CD11b, Mo2 mAb recognizes a CD14 epitope
expressed on mature monocytes. After correction for unspe-
cific binding, specific mean fluorescence intensity was given in
channels on a log10 scale. Cell culture or treatment of PBMCs
with lovastatin for 24 h did not affect surface expression of
monocyte-specific CD14 (data not shown).
Endothelial cell culture and adhesion assay. Human um-
bilical vein endothelial cells (HUVECs) were grown in low
serum endothelial cell growth medium (PromoCell), as de-
scribed (18). Purity was assessed by morphology and Factor
VIII expression. HUVECs derived from one preparation
(passage 2) were grown to confluence in 48-well plates, fixed
with 2% paraformaldehyde and stored desiccated and pro-
tected from light, as described (16). This procedure resulted in
little retraction of HUVECs from their tight junctions and no
significant change in surface expression of ICAM-1 or other
receptors (e.g., platelet endothelial cell adhesion molecule-1),
as assessed by immunofluorescence, and minimized interassay
variations that were found when using living HUVECs, partic-
ularly in longitudinal adhesion studies. Isolated monocytes
were resuspended (105/ml) in medium 199 with 10 mmol/liter
HEPES buffer (M199). HUVECs were washed with M199
before addition of monocytes and incubated at 37°C, 5% CO2,
90% humidity for 60 min (16). The cell suspension was
withdrawn, HUVECs were washed twice with M199, and
inverted plates were centrifuged (50g, 5 min). Cells were then
treated with formalin/ethanol and stained with Coomassie/
Giemsa solution. Adherent monocytes were counted in 20
separate areas with the use of light microscopy (3400) and
expressed as percent of cells added. Monocytes were pre-
treated with CD11b (mAb 44) or isotype control mAb (Sero-
tec, all 10 mg/ml) for 15 min, and for in vitro assays, cells were
stimulated with monocyte chemotactic protein 1 (MCP-1,
10 ng/ml) for 10 min, and allowed to adhere for 30 min.
Inhibition of adhesion with CD11b mAb was obtained with or
without preincubation of monocytes with gamma-globulin to
block Fc receptors. A F(ab9)2 fragment of the mAb was also
effective (data not shown).
Cholesterol and triglyceride determination. Plasma con-
centrations of total, LDL and high density lipoprotein (HDL)
cholesterol and triglycerides were determined by standard
enzymatic methods (Boehringer Mannheim test kit). All other
reagents were from Sigma Chemical Co.
Statistical analysis. All data were expressed as mean
value 6 SD and were analyzed by analysis of variance com-
bined with a Scheffe´ F test as a multiple comparison procedure
and by t test where appropriate. Comparison was made be-
tween control subjects and patients with hypercholesterolemia,
and between patients before and after treatment. Values of
p , 0.05 were considered significant.
Abbreviations and Acronyms
CHD 5 coronary heart disease
GTP 5 guanosine triphosphate
HDL 5 high density lipoprotein
HMG-CoA 5 3-hydroxy-3-methyl-glutaryl coenzyme A
HUVECs 5 human umbilical vein endothelial cells
ICAM-1 5 intercellular adhesion molecule-1
LDL 5 low density lipoprotein
mAb 5 monoclonal antibody
MCP-1 5 monocyte chemoattractant protein-1
PBMCs 5 peripheral blood mononuclear cells
1213JACC Vol. 30, No. 5 WEBER ET AL.
November 1, 1997:1212–7 HMG-CoA REDUCTASE INHIBITORS AND MONOCYTE ADHESION
Results
Lovastatin affects monocyte CD11b expression and adhe-
sion to endothelium. We studied the effect of lovastatin on
monocyte CD11b surface expression in vitro. After gating for
CD14-positive monocytes, untreated cells showed marked
CD11b expression, which remained constant for 24 h of cell
culture. Treatment with lovastatin dose-dependently reduced
CD11b expression (Fig. 1A) from 328 6 17 to 247 6 28
channels at 10 mmol/liter (p , 0.05, n 5 3). The effect was not
detectable at 2 h and less pronounced at 12 h of incubation
(287 6 18 channels). Co-incubation with mevalonate (500
mmol/liter) but not LDL (50 mg/ml) reversed the reduction of
CD11b expression by lovastatin (Fig. 1A), suggesting that
isoprenoid intermediates but not cholesterol are crucial for
expression of CD11b. Chemokines such as MCP-1 are known
to upregulate CD11b/CD18 expression on leukocytes (12). In
our assay, MCP-1 minimally increased monocyte CD11b ex-
pression, but treatment with lovastatin still decreased CD11b
expression on MCP-1–stimulated monocytes (Fig. 1A, p , 0.05
vs. untreated cells, n 5 3).
Because the adhesiveness of the ICAM-1 receptor CD11b/
CD18 has been shown to require its activation independent of
changes in surface expression (12), we studied effects of
lovastatin on CD11b-dependent adhesion to fixed HUVECs
expressing ICAM-1 but not vascular adhesion molecule-1
(VCAM-1) or E-selectin (14,18). MCP-1 markedly stimulated
adhesion of monocytes to fixed HUVECs (Fig. 1B) from
0.60 6 0.18% to 1.15 6 0.22% (p , 0.01, n 5 4). Preincubation
of monocytes with mAb to CD11b reduced adhesion of
unstimulated monocytes and completely inhibited MCP-1–
stimulated increases in adhesion to fixed HUVECs (Fig. 1B),
whereas isotype control mAb had no effect (data not shown).
This finding confirms the involvement of CD11b/CD18 and
shows that its activation mediates the increase in monocyte
adhesiveness. Pretreatment of monocytes for 24 h with lova-
statin (10 mmol/liter) reduced adhesion of unstimulated mono-
cytes to HUVECs and markedly inhibited adhesion of MCP-
1–stimulated monocytes (0.29 6 0.05%, p , 0.01, n 5 4) to
HUVECs (Fig. 1B). Combination with CD11b mAb showed no
additional inhibition, whereas coincubation with mevalonate
(500 mmol/liter) but not with LDL (50 mg/ml) reversed the
effect of lovastatin (Fig. 1B). Hence, lovastatin may interfere
with activation of CD11b/CD18 adhesiveness by chemokines in
monocytes as a result of decreased availability of isoprenoid
intermediates.
Effect of lovastatin or simvastatin on monocytes from
hypercholesterolemic patients. We next studied whether
HMG-CoA reductase inhibitors are also effective in monocytes
from patients with hypercholesterolemia. Total, LDL or HDL
cholesterol and triglyceride plasma levels in control donors and
in patients before and after treatment are shown in Figure 2A.
Consistent with previous results (15), we found that the
adhesion to endothelium ex vivo of monocytes from patients
with isolated hypercholesterolemia was markedly greater (Fig.
2B) than that of monocytes from healthy control subjects with
normal plasma cholesterol levels (p , 0.001, n 5 7). The
adhesion of monocytes from control subjects ranged from
0.43% to 1.01% (mean 6 SD 0.65 6 0.18%), whereas adhesion
of monocytes from patients was greatly enhanced (range 2.4%
to 9.8%, mean 5.3 6 2.3%). Preincubation with a CD11b mAb
inhibited the adhesion of monocytes isolated from patients
before treatment to 2.6 6 1.2%, indicating the involvement of
CD11b/CD18 in increased monocyte binding to fixed
HUVECs. Treatment of patients with lovastatin (20 to
40 mg/day, n 5 3) or simvastatin (20 mg/day, n 5 4) for 6 weeks
reduced plasma levels of total and LDL cholesterol while
increasing that of HDL cholesterol (Fig. 2A). The adhesive-
ness of monocytes isolated from patients was dramatically
reduced after 6 weeks of treatment (range 0.66% to 2.9%,
Figure 1. Effect of lovastatin (LOV) on monocyte CD11b expression
(A) and adhesion to endothelium (B). Monocytes were treated with or
without lovastatin (1 or 10 mmol/liter), mevalonate (MEV, 500 mmol/
liter) or LDL (50 mg/ml) for 24 h and carefully harvested, pretreated
with CD11b mAb (10 mg/ml) for 20 min on ice or prestimulated with
MCP-1 (10 ng/ml) for 10 min, as indicated. A, Cells were stained with
mAb to CD14, CD11b or isotype control and analyzed by flow
cytometry. After gating for CD14-positive cells, specific mean fluores-
cence intensity (sMFI) for CD11b was recorded. Data expressed in
channels are mean value 6 SD of three independent experiments. B,
After coincubation with fixed endothelium for 30 min at 37°C, the
number of adherent monocytes was determined. Data expressed as
percent of cells added are mean 6 SD of four independent experi-
ments performed in triplicate.
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mean 1.67 6 0.65%; p , 0.01, n 5 7) (Fig. 2B). The changes
in cholesterol plasma levels were not significantly correlated
with those in monocyte adhesiveness (data not shown).
To elucidate possible mechanisms for changes in monocyte
adhesiveness, we studied monocyte CD11b expression ex vivo.
After gating for CD14-positive monocytes, CD11b expression
on monocytes isolated from hypercholesterolemic patients
before treatment ranged from 286 to 366 channels (specific
mean fluorescence intensity) (mean 319 6 24, n 5 7), com-
pared with 261 to 322 channels (mean 290 6 21) in control
donors (Fig. 2C). Treatment with lovastatin or simvastatin for
6 weeks slightly reduced monocyte CD11b expression to 283 6
24 channels (p , 0.05, n 5 7). The regulation of CD11b
surface expression has been dissociated from its adhesive
function (19,20). Therefore, the pronounced decrease in ad-
hesion after treatment with lovastatin or simvastatin may be
independent of the slight reduction in CD11b expression.
Discussion
Monocyte accumulation after adhesion to endothelium and
extravasation plays a crucial role in the formation of athero-
mas, to perpetuation of a chronic inflammatory reaction and
lipid deposition into monocyte-derived foam cells (11). These
cells further contribute to the instability and disruption of
atherosclerotic plaques by secretion of proteolytic enzymes
that degrade extracellular matrix constituents, and may thus
trigger clinical manifestations of atherosclerosis (21). We show
that inhibitors of HMG-CoA reductase decrease CD11b-
dependent adhesion of unstimulated and MCP-1–stimulated
monocytes to human endothelium in vitro. Treatment with
HMG-CoA reductase inhibitors is also effective in reducing the
increased adhesiveness to fixed endothelium of monocytes
isolated from hypercholesterolemic patients ex vivo. The re-
duction in adhesiveness after HMG-CoA reductase inhibition
was more marked than changes in CD11b expression. This
suggested that the decrease in monocyte adhesion was due to
a reduction in adhesiveness of CD11b/CD18, which can occur
independently of its surface expression. The adhesiveness of
CD11b/CD18 may rather be mediated by a small subpopula-
tion of molecules undergoing conformational changes in re-
sponse to stimulation (22). Moreover, the changes in adhesive-
ness of monocytes ex vivo were poorly correlated with the
reduction of total cholesterol and LDL cholesterol plasma
levels. The reversibility with mevalonate but not with LDL in
vitro also demonstrated that the reduction of CD11b expres-
sion and CD11b-dependent adhesion of monocytes was due to
decreased availability of isoprenoid cholesterol precursors, but
not of cholesterol. Furthermore, increased cholesterol uptake
is assumed to compensate for a reduction in cholesterol
synthesis during cell culture (9).
Potential mechanisms of action. Isoprenoid molecules
posttranslationally modify various proteins and mediate
protein-membrane anchoring and protein-protein interactions.
Some of the isoprenylated proteins identified are small
guanosine triphosphate (GTP)-binding proteins of the ras
family, such as rac and rho, as well as the gamma subunits of
heterotrimeric G proteins (6). Chemoattractant receptors are
coupled to GTP-binding protein heterotrimers, and integrin-
dependent binding of leukocytes to endothelium can involve a
G-protein regulated activation event (23). Lovastatin has been
shown to inhibit Ca21 influx stimulated by G-protein–coupled
receptors and localization of ras-like proteins into the mem-
brane of monocytic cells (7). Expression of a constitutively
active form of the GTPase R-ras results in activation of beta1
and beta3 integrin avidity, and inactivation of the GTPase rho
Figure 2. Plasma lipid levels (A), adhesion to endothelium (B) and
CD11b expression of isolated monocytes (C) in control donors (con-
trols) and patients with hypercholesterolemia (patients) before (pre)
or after (post) treatment with lovastatin (20 to 40 mg/day) or simva-
statin (20 mg/day) for 6 weeks. A, Plasma cholesterol (Chol) and
triglyceride (Triglyc) levels were determined by standard enzymatic
assays. B and C, Monocytes were isolated by magnetic cell separation.
After coincubation with fixed endothelium for 60 min at 37°C, the
number of adherent monocytes was determined. Experiments were
performed in triplicate, and data are expressed as percent of cells
added (B). Monocytes were also stained for CD14, CD11b or isotype
control, analyzed by flow cytometry and, after gating for CD14-positive
cells, specific mean fluorescence intensity (sMFI) for CD11b was
recorded and expressed in channels (C). Shown are individual values
and mean value 6 SD of control subjects (n 5 7, open squares) and
patients (n 5 7) before (closed circles) or after (open circles)
treatment. L 5 liter.
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suggests its participation in signaling by way of chemoattrac-
tant receptors to trigger activation of CD11b/CD18 (24,25).
Hence, HMG-CoA reductase inhibitors may impair activation
of CD11b/CD18 involving small GTPases or stimulation of
G-protein-heterotrimer coupled receptors by MCP-1 or other
autocrine chemokines. Alternatively, these drugs may act by
interfering with the transport, dimerization or anchoring of
CD11b/CD18 in the plasma membrane to maintain its expres-
sion on the cell surface. HMG-CoA reductase inhibitors may
affect GTP-binding protein-membrane or protein-protein in-
teractions by preventing their prenylation or farnesylation,
thus impairing activation and expression of CD11b/CD18.
Increased adhesion of monocytes to endothelium ex vivo
was recently shown (15) in patients with hypercholesterolemia;
however, inhibitory effects of HMG-CoA reductase inhibitors
could not be demonstrated. In contrast, the use of fixed
endothelium from one preparation minimized interassay vari-
ations, particularly in longitudinal adhesion studies (16), and
may have thus enabled us to detect inhibitory effects of
HMG-CoA reductase inhibitors on monocyte adhesion. The
increased adhesion of monocytes from hypercholesterolemic
patients has been attributed (15,26) to abnormal monocyte
function with respect to eicosanoid metabolism and superoxide
anion generation. Hence, HMG-CoA reductase inhibitors may
act by inhibiting superoxide anion formation and subsequent
LDL oxidation by an NAPDH oxidase in activated monocytes
that requires assembly of various cytosolic components includ-
ing small GTP-binding proteins (6,8). Consistently, intake of
the antioxidant vitamin C has been demonstrated to prevent
the increased CD11b-dependent adhesiveness of monocytes
isolated from smokers (16), which may involve similar oxida-
tive pathways.
Limitations of the study. A certain limitation of this study
is the small number of patients. However, a small sample size
does not preclude the demonstration of potential mechanisms
underlying the action of HMG-CoA reductase inhibitors, since
the effect of these drugs on monocyte adhesion was highly
significant. A second aspect involves the in vitro studies that
required culture of monocyte preparations over 24 h for
treatment with lovastatin. Because CD11b expression and the
range of monocyte adhesion remained almost unchanged
during this period, and because the effects of lovastatin were
comparable to those seen in freshly isolated monocytes, this
assay allows valuable insights into mechanisms responsible
for the effects of HMG-CoA reductase inhibitors. Thirdly,
the isolation procedure may result in a partial activation of
monocytes. Thus, the results of this study may reflect the
adhesive properties of monocytes that may be activated to
some degree.
Conclusions. The reductions in relative risk of CHD after
simvastatin reported in the Scandinavian Simvastatin Survival
Study (4S) trial (1) did not significantly differ between quartiles
for any lipid variable. This finding may be due to effects on
crucial mechanisms involved in atherogenesis other than cho-
lesterol lowering. Moreover, the beneficial efficacy of prava-
statin in the Regression Growth Evaluation Statin Study
(REGRESS) study (3) is reduced by smoking, which increases
oxidative stress and monocyte adhesiveness (16). In conclu-
sion, the reduction of monocyte CD11b expression and
CD11b-dependent adhesiveness to endothelium by HMG-
CoA reductase inhibitors provides a novel mechanism of
action of these compounds and may explain their beneficial
effects in the prevention and treatment of CHD (1,2). Our
results highlight actions of HMG-CoA reductase inhibitors
that are not related to their cholesterol-lowering effects, but
may rather be due to interference with cellular isoprenoid
metabolism and prenylation-dependent processes.
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